Scientific Frontline: Extended "At a Glance" Summary: Blood Pressure-Lowering Drug with a Light Switch
The Core Concept: Researchers have developed and observed a light-switchable blood pressure medication that alters its molecular shape and potency when exposed to specific wavelengths of light. This advancement allows the drug's therapeutic effects to be modulated with precise timing and localization within the body.
Key Distinction/Mechanism: Unlike standard beta blockers, the experimental drug photoazolol-1 contains an integrated azobenzene atomic group functioning as a synthetic light switch. When irradiated with violet light, this atomic group flips, changing the molecule from a straight to a bulkier, bent shape. While the molecule remains inside the binding pocket of the β-adrenergic receptor, its altered form binds less effectively, reducing its capacity to block adrenaline and dynamically altering the receptor's activity.
Origin/History: The switchable molecule was synthesized by collaboration partners at the Consejo Superior de Investigaciones Científicas in Barcelona. Its exact molecular transformation mechanisms were subsequently mapped by researchers at the Paul Scherrer Institute (PSI) using the SwissFEL X-ray free-electron laser, with the findings recently published in the journal Angewandte Chemie.



.jpg)



.jpg)

.jpg)
.jpg)



.jpg)




